Discover 1,609 paid clinical trials in Raleigh, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,609
A Phase 1/1b Study of IAM1363 in HER2 Cancers
for
HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer,
Location: Durham NC, Fairfax VA, New Brunswick NJ, Cleveland OH,
Sponsor: Iambic Therapeutics, Inc
Sex: All
Age: 18+
Code: NCT06253871
Phase1, Recruiting
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
for
Solid Tumors
Location: Durham NC, Spartanburg SC, Fairfax VA,
Sponsor: ORIC Pharmaceuticals
Sex: All
Age: 18+
Code: NCT05315700
Phase1, Phase2, Recruiting
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
for
Low-grade Glioma, Advanced Solid Tumor
Location: Durham NC, Washington DC, Philadelphia PA, New York NY,
Sponsor: Day One Biopharmaceuticals, Inc.
Sex: All
Age: 0 - 25
Code: NCT04775485
Phase2, Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
for
Relapsed or Refractory Multiple Myeloma
Location: Durham NC, Roanoke VA, Norfolk VA, Fredericksburg VA,
Sponsor: Celgene
Sex: All
Age: 18+
Code: NCT05519085
Phase3, Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
for
Breast Cancer, Breast Cancer Metastatic,
Location: Durham NC, Charlotte NC, Augusta GA, Atlanta GA,
Sponsor: Incyclix Bio
Sex: All
Age: 18+
Code: NCT05735080
Phase1, Phase2, Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
for
Extensive-Stage Small Cell Lung Cancer
Location: Durham NC, Roanoke VA, Marietta GA, Cincinnati OH,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06646276
Phase3, Recruiting
Exactech Shoulder Post Market Clinical Follow-up Study